Skip to main content
Research
Research

Melanoma Research Institute of Excellence

Support the Melanoma Research Institute of Excellence

Contact

Mitchell Berkowitz
Program Manager
Melanoma Research Institute of Excellence

Contact

Shingo Sato
  • Associate Program Manager
  • Director of Database Design and Utilization
Melanoma Research Institute of Excellence

Clinical Trials

Marlana Orloff, MD

Principal Investigator

A Phase 1/2 Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
A Prospective Natural History Study in Uveal Melanoma
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-Line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma
A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients with Inoperable Advanced and/or Metastatic Uveal Melanoma
A Phase II, Multi-centre, Open label, Randomised Study to Evaluate the Anti-tumour Activity of Roginolisib in Patients with Advanced/Metastatic Ocular/Uveal Melanoma
Expanded Access Program of AMTAGVI that is Out of Specification for Commercial Release
APG-115 and Pembrolizumab Individual Patient Expanded Access for the Treatment of Metastatic Uveal Melanoma

Takami Sato, MD, PhD

Principal Investigator

Acquisition of Tumor Tissue for Laboratory Research
International Collaborative Study in Development of New Cancer Immunotherapies
A Randomized Phase ll Study of Adjuvant Sunitinib or Valproic Acid in High-Risk Patients with Uveal Melanoma
Phase II Study of Adjuvant Nivolumab in Patients with Resected Stage IIb/IIc Melanoma
A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers

Rino Seedor, MD

Principal Investigator

A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma
A Phase I/II Study of Tebentafusp-tebn in Combination with Liver-Directed Therapies for the Treatment of Metastatic Uveal Melanoma
Neoadjuvant Tebentafusp in Patients with Locally Advanced, Unresectable Primary Uveal Melanoma
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients With Advanced Melanoma (PET-Stop)
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)
A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma
A Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician's Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen [IGNYTE-3]
A prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate efficacy, safety, and tolerability of IMA203 versus investigator's choice in patients with previously treated, unresectable or metastatic cutaneous melanoma (ACTengine® IMA203-301)
Phase 1/2 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with nivolumab in patients with recurrent and/or refractory solid tumors (ACTengine® IMA203-101)
A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients (EA6244)
Clinical Research Staff
Go Back to Melanoma Research Institute of Excellence